Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Brigham and Womens Hospital, shared a post on LinkedIn:
“Oliver Soehnlein led our update on inflammation in atherosclerosis and the opportunities for novel therapies to quench the smoldering within the plaque and improve clinical outcomes. Table 1 features “Emerging preclinical interference strategies aimed at reducing atherosclerosis” and Figure 5 presents a “Timeline of major milestones of research connecting inflammation with atherosclerosis” which we hope ongoing studies and clinical trials will soon extend as we seek the “sweet spot” of calming inflammation while avoiding undue interference with host defenses or tumor surveillance. Libby and Soehnlein, Inflammation in atherosclerosis: Lessons and therapeutic implications, Immunity (2025),”
Title: Inflammation in atherosclerosis: Lessons and therapeutic implications
Authors: Peter Libby, Oliver Soehnlein
Read full article here.
Stay updated with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia